Facility Deficiencies Drive Rising CRL Rates For CDER Biologics

 
• By Bridget Silverman
  
bioreactor
The complexity of advanced biologic manufacturing can delay US FDA approval. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Manufacturing

More from Compliance